Kamada Announces Launch of a Comprehensive Post-Marketing Research Program for CYTOGAM®

Program Aimed at Generating Key Data in Support of the Benefits of CYTOGAM® in the Management of Cytomegalovirus (CMV) in Solid Organ TransplantationA Total of 10 Studies will be Conducted in Collaboration with Leading U.S. Physicians, Primarily as Investigator-Initiated Studies (IIS)Results of the Planned Studies are Expected to be Published and/or Presented in Peer Reviewed Industry Journals and Medical Meetings in the Coming Years REHOVOT, Israel, and HOBOKEN, N.J., May 05, 2025 (GLOBE NEWSWIRE) -- Kamad ...